Keep saying it, but it is a peer-reviewed editorial that breaks down each of the issues that were identified and analyzes all of the component parts as to the cause of bias in the trial results.
Once again from the Neuro-Oncology Journal author guidelines here is the facts:
"Reviews and Editorials that cover subjects of timely interest and importance to cancer researchers. (These are usually written by invitation of the Editor in Chief. Authors wishing to write a review or an editorial should send a letter to the Editor in Chief outlining the proposed article. All reviews that the editors consider suitable, whether invited or not, will be subjected to full peer review.)."
Clearly your post is incorrect. And it clearly documents a pattern of bias in the trial design and analysis.
Market Data 
Markets 
AI
